**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO:** **27791**

**Manuscript Type: Original Article**

***Retrospective Cohort Study***

**Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia**

Gomez JM *et al*. Association between gastric intestinal metaplasia and dysplasia

**Justin M Gomez, James T Patrie, Wissam Bleibel, Jeanetta W Frye, Bryan G Sauer, Vanessa M Shami, Edward B Stelow, Christopher A Moskaluk, Andrew Y Wang**

**Justin M Gomez, Wissam Bleibel, Jeanetta W Frye, Bryan G Sauer, Vanessa M Shami, Andrew Y Wang,** Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908, United States

**James T Patrie,** Division of Biostatistics and Epidemiology, University of Virginia, Charlottesville, VA 22908, United States

**Edward B Stelow, Christopher A Moskaluk,** Department of Pathology, University of Virginia, Charlottesville, VA 22908, United States

**Author contributions:** Gomez JM and Wang AY contributed equally to this work; Gomez JM, Bleibel W, Frye JW, Sauer BG, Shami VM, Moskaluk CA and Wang AY designed the research; Gomez JM, Patrie JT, Moskaluk CA and Wang AY performed the research; Patrie JT contributed statistical/analytic tools; Stelow EB and Moskaluk CA provided pathological analysis; Gomez JM, Patrie JT and Wang AY analyzed the data; Gomez JM, Patrie JT, Wang AY wrote the paper; Bleibel W, Frye JW, Sauer BG, Shami VM, Stelow EB, Moskaluk CA and Wang AY critically revised the paper for important intellectual content.

**Institutional review board statement:** This study was reviewed and approved by the University of Virginia Institutional Review Board for Health Sciences Research.

**Informed consent statement:** Informed consent was obtained prior to all endoscopic procedures as part of routine patient care. However, this was a retrospective cohort study that involved materials (data, documents, or records) that were collected solely for non-research purposes (such as medical diagnosis and treatment). Therefore, informed consent was not required for the purposes of this study given minimal risk to subjects.

**Conflict-of-interest** **statement:** The authors have no conflicts of interest, financial or otherwise, to report with respect to this manuscript.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

# Manuscript source: Invited manuscript

**Correspondence to:** **Andrew Y Wang, MD, AGAF, FACG, FASGE, Associate Professor** of Medicine, **Co-Medical Director** of Endoscopy, Division of Gastroenterology and Hepatology, University of Virginia, Box 800708, 1301 Jefferson Park Avenue, Charlottesville, VA 22908, United States. ayw7d@virginia.edu

**Telephone:** +1-434-9241653

**Fax:** +1-434-2447590

**Received:** June 16, 2016

**Peer-review started:** June 17, 2016

**First decision:** July 27, 2016

**Revised:** October 13, 2016

**Accepted:** November 16, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To determine which clinical factors might be associated with gastric intestinal metaplasia (IM) in a North American population.

***METHODS***

Pathology and endoscopy databases at an academic medical center were reviewed to identify patients with and without gastric IM on biopsies for a retrospective cohort study. Patient demographics, insurance status, and other clinical factors were reviewed.

***RESULTS***

Four hundred and sixty-eight patients with gastric IM (mean age: 61.0 years ± 14.4 years, 55.5% female) and 171 without gastric IM (mean age: 48.8 years ± 20.8 years, 55.0% female) were compared. The endoscopic appearance of atrophic gastritis correlated with finding gastric IM on histopathology (OR 2.05, *P* = 0.051). Gastric IM was associated with histologic findings of chronic gastritis (OR 2.56, *P* < 0.001), gastric ulcer (OR 6.97, *P* = 0.015), gastric dysplasia (OR 6.11, *P* = 0.038), and gastric cancer (OR 6.53, *P* = 0.027). Histologic findings of Barrett’s esophagus (OR 0.28, *P* = 0.003) and esophageal dysplasia (OR 0.11, *P* = 0.014) were inversely associated with gastric IM. Tobacco use (OR 1.73, *P* = 0.005) was associated with gastric IM.

***CONCLUSION***

Patients who smoke or have the endoscopic finding of atrophic gastritis are more likely to have gastric IM and should have screening gastric biopsies during esophagogastroduodenoscopy (EGD). Patients with gastric IM are at increased risk for having gastric dysplasia and cancer, and surveillance EGD with gastric biopsies in these patients might be reasonable.

**Key words:** Gastric; Intestinal metaplasia; Atrophic gastritis; Biopsies; Esophagogastroduodenoscopy

© **The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastric intestinal metaplasia (IM) is a precursor to gastric adenocarcinoma. There are no North American consensus recommendations as to which patients might benefit from esophagogastroduodenoscopy (EGD) with biopsy for screening or surveillance for gastric IM.Patients who smoke or have the endoscopic finding of atrophic gastritis are more likely to have gastric IM and should have screening gastric biopsies during EGD. Patients with gastric IM are at increased risk for developing gastric dysplasia and cancer, and surveillance EGD with gastric biopsies in these patients might be reasonable.

Gomez JM, Patrie JT, Bleibel W, Frye JW, Sauer BG, Shami VM, Stelow EB, Moskaluk CA, Wang AY. Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia. *World J Gastrointest Endosc* 2016; In press

**INTRODUCTION**

Gastric cancer is the fifth leading type of cancer worldwide, with 952000 new cases diagnosed in 2012. With 723000 reported deaths in 2012, gastric cancer is the third most common cause of cancer-related mortality[[1](#_ENREF_1),[2](#_ENREF_2)]. The annual incidence of gastric cancer in 2013 based upon the SEER database was 7.5 per 100000 population with an annual death rate of 3.5 cases per 100000 in the United States (US) population[[3](#_ENREF_3)]. The lower prevalence of gastric cancer in Western countries is also associated with the diagnosis of gastric cancer at a later stage, which results in a poor 5-year survival of 20% within the US[[4](#_ENREF_4)]. Patients diagnosed with early stage gastric carcinoma have a significantly better prognosis with 5-year survival rates approaching 90%[[5](#_ENREF_5),[6](#_ENREF_6)].

The mechanisms responsible for gastric carcinogenesis are not completely known. However, gastric cancer is thought to arise from a premalignant cascade potentially initiated by *Helicobacter pylori* (*H. pylori*)infection[[7-9](#_ENREF_7)]. In 1988, Correa[[10](#_ENREF_10)] first described a pathway through which premalignant lesions could become gastric cancer. This cascade progresses from non-atrophic gastritis to atrophic gastritis, gastric intestinal metaplasia (IM), gastric dysplasia, and ultimately gastric carcinoma. Gastric IM has since become well established as a premalignant lesion that is associated with an increased risk of gastric carcinoma[[11-13](#_ENREF_11)]. The largest observational study of patients with precancerous gastric lesions in the Western world included 61707 individuals with gastric IM and found an annual incidence of progression to gastric cancer of 0.25%[[14](#_ENREF_14)].

Gastric IM is characterized by a change from the normal glandular epithelium found in the stomach to a small-intestinal phenotype. The pathogenesis of gastric IM remains unclear but is thought to involve environmental stimuli that lead to differentiation of the gastric stem cells towards an intestinal phenotype[[15-17](#_ENREF_15)]. Pathologically, gastric IM can be recognized by the presence of a simple columnar epithelium containing Paneth cells, absorptive cells, and goblet cells[[15](#_ENREF_15)]. Additionally, gastric IM may be classified further based on histologic appearance into complete (type I) and incomplete (type II or III). Complete (type I) gastric IM is recognized by the presence of a small intestinal mucosal phenotype with goblet cells containing sialomucins interspersed between absorptive cells and a well-defined brush border. Incomplete (type II or III) gastric IM is characterized by a colonic mucosal phenotype with tortuous crypts lined by tall columnar cells containing sulfomucins[[18](#_ENREF_18)]. The incomplete pattern of gastric IM is associated with the greatest risk of progression to gastric cancer[[19-25](#_ENREF_19)]. A study completed in Spain found that the incidence of gastric cancer in patients with incomplete IM was 16 (18.2%) out of 88 patients and 1 (0.96%) out of 104 patients with complete IM when followed for a mean of 12.8 years[[26](#_ENREF_26)]. However, in practice pathologists, even at most academic institutions, do not typically make the distinction between different types of gastric IM. The two types of incomplete IM are based on sulfomucin content, which cannot be determined by hematoxylin and eosin (H and E) staining alone. Pathologically, this distinction may be difficult to make as incomplete and complete gastric IM can coexist, and the finding of gastric IM can be very focal even on a small biopsy specimen.

The prevalence of gastric IM in the general population is difficult to assess due to the fact that it is an asymptomatic lesion that can only be found on histologic evaluation of gastric tissue, typically obtained by esophagogastroduodenoscopy (EGD). In 2010, Sonnenberg *et al*[[27](#_ENREF_27)] published the results from a retrospective study of 78985 patients undergoing EGD and gastric biopsy in the US and found that the prevalence of gastric IM was 7%. Within this patient population there was a continuous age-dependent rise in finding gastric IM from age 0 to 90 years. Furthermore, the frequency of gastric IM is geographically variable, as shown by a Chinese study that found gastric IM in 29.3% of 1630 consecutive patients with *H. pylori* infection presenting for a screening EGD[[28](#_ENREF_28),[29](#_ENREF_29)].

Guidelines put forth by the European Society of Gastrointestinal Endoscopy (ESGE) in 2012 recommended that at least two biopsies from the antrum (greater and lesser curvature) and two biopsies from the corpus (greater and lesser curvature) be taken for adequate assessment of premalignant gastric conditions. These guidelines recommended that patients with extensive atrophic gastritis or gastric IM should be offered surveillance endoscopy every 3 years. They also recommended that if *H. pylori* infection is diagnosed, then eradication should be offered to decrease the progression to dysplasia and carcinoma[[30](#_ENREF_30)]. Despite strong epidemiologic and molecular data linking gastric IM and gastric carcinoma, there are currently no North American consensus guidelines as to which patients might benefit from EGD with biopsy for screening or surveillance endoscopy[[22](#_ENREF_22)]. The aim of this study was to determine what clinical factors might be associated with gastric IM in a US population so as to identify potential indications for screening and/or surveillance by using EGD with gastric biopsies.

**MATERIALS AND METHODS**

This study was conducted at University of Virginia Medical Center, a single tertiary-care hospital that performs both outpatient and inpatient endoscopic procedures from patients from a wide geographic area (including significant portions of Virginia, West Virginia, and Tennessee) using an open-access model. This study was approved by our institutional review board.

Pathology and endoscopy databases were reviewed to identify patients with and without gastric IM. Patients who had pathology-confirmed gastric IM from 2005-2011 were extracted from a dedicated pathology database. Using an endoscopic billing database, a control group of patients was established by reviewing 300 consecutive patients who had undergone EGD with biopsies (186 patients had gastric biopsies) from March to June 2011, from which 171 patients were identified who had gastric biopsies without gastric IM. The rate of gastric IM in this control group of patients was 5%, which we have previously reported[[31](#_ENREF_31)]. All upper endoscopies were performed by experienced gastrointestinal endoscopists, and all pathological diagnoses included in this study were made by academic pathologists at our institution. Diagnosis of gastric IM was made histologically on H and E-stained slides. Diagnosis of *H. pylori* infection was made histologically using immunohistochemical stains.

Electronic medical records, including pathology and endoscopy reports, were reviewed and information about patient demographics, insurance status, and possible risk factors for the development of gastric IM and gastric dysplasia was collected. Potential risk factors of interest included a first-degree family history of gastric cancer, presence of *H. pylori* infection on gastric biopsy, and certain clinical indications for endoscopy. Additional patient characteristics of interest included social factors such as lifetime history of tobacco use, alcohol use (if reported within the past year), and acid suppression therapy with proton-pump inhibitors or H2-receptor antagonists. Unfortunately, ethnic background was not available for analysis, as data from earlier patients were derived from a different electronic medical record system that did not reliably capture this information.

Frequency data were summarized as percentages and analyzed by exact logistic regression. Continuous variables were summarized by the median and range of distribution. Univariate and age-adjusted multivariate analyses were conduct by way of exact logistic regression to compare patient outcomes between those with and without gastric IM. A two-sided *P* ≤ 0.05 decision rule was established a priori as the null hypothesis rejection criterion, and 95%CI construction for the odds ratio (OR) was based on the Mid-P method[[32](#_ENREF_32)]. The exact statement of the SAS version 9.2 LOGISTIC procedure was utilized to conduct the exact logistic regression analyses (SAS Institute Inc., Cary, NC).

**RESULTS**

***Patients and demographics***

Four hundred and sixty-eight patients (mean age: 61.0 years ± 14.4 years, 55.5% female) with gastric IM diagnosed on gastric histopathology and 171 patients (mean age: 48.8 years ± 20.8 years, 55.0% female) without gastric IM on gastric biopsies were included in this study. Refer Table 1 for patient characteristics.

Patients with pathologically-diagnosed gastric IM were statistically more likely to be older (*P* < 0.001). When insurance status was evaluated, patients with Medicare were significantly more likely to have gastric IM [OR 1.94 (1.20, 3.17), *P* = 0.007], whereas patients with private insurance were less likely to have gastric IM [OR 0.66 (0.44, 0.99), P = 0.047]. We did not detect a statistically significant association between a positive family history of gastric cancer and gastric IM. A history of recent alcohol abuse was not associated with gastric IM; whereas, a lifetime history of tobacco abuse was significantly associated with gastric IM [OR 1.73 (1.18, 2.55), *P* = 0.005].

***Indication for endoscopy***

Four hundred and eighteen patients with pathology-proven gastric IM and all 171 controls without gastric IM underwent EGD with gastric biopsies. Among indications for procedures (Table 2), Barrett’s esophagus [OR 0.32 (0.12, 0.92), *P* < 0.034] was associated with an inverse association with gastric IM on multivariate analysis. Whereas, weight loss [OR 1.81 (0.95, 3.66), *P* = 0.073] correlated with a trend towards increased frequency of gastric IM [OR 1.81 (0.95, 3.66), *P* = 0.073].

***Endoscopic findings***

The two most frequent endoscopic findings (Table 3) on EGD (prior to any pathologic confirmation) in this patient population were gastritis (137/589, 23.3% for all patients) and gastric mucosal nodularity (104/589, 17.7%).

Endoscopic findings of a gastric mass [OR 8.84 (1.88, ∞), *P* = 0.005] and atrophic gastritis [OR 2.05 (1.00, 4.58), *P* = 0.051] were significantly associated with finding gastric IM on histopathology by multivariate analysis. The endoscopic appearance of and duodenal polyps [OR 4.21 (0.81, ∞), *P* = 0.081] trended towards an increased association with finding gastric IM on biopsies. On multivariate analysis, the esophageal abnormalities of an esophageal mass [OR 0.04 (0.01, 0.16), *P* < 0.001], esophagitis [OR 0.49 (0.26, 0.91), *P* = 0.023], and Barrett’s esophagus [OR 0.56 (0.26, 1.21), *P* = 0.134] were found to inversely correlate with finding gastric IM on histopathology.

***Histopathological diagnoses***

When all patients with and without gastric IM were considered, the most frequent histologic diagnoses encountered were chronic gastritis (305/639, 47.7%) and gastric polyp (46/639, 7.2%). Histologic diagnoses and associations for patients with and without gastric IM found on surgical pathology are shown in Table 4.

On univariate and multivariate analyses, patients with biopsy-proven gastric IM were found to have an increased association with the following gastric histopathological diagnoses (multivariate odds ratios are reported): Chronic gastritis [OR 2.56 (1.75, 3.76), *P* < 0.001], gastric ulcer [OR 6.94 (1.47, ∞), *P* = 0.015], gastric dysplasia [OR 6.11 (1.07, 131.57), *P* = 0.038], gastric cancer [OR 6.53 (1.17, 139.41), *P* = 0.027], and autoimmune metaplastic atrophic gastritis [OR 5.64 (1.36, ∞), *P* = 0.035]. Patients with *H. pylori* infection on gastric pathology also had a significant association with gastric IM [OR 3.07 (1.33, 8.20), *P* = 0.007].

Patients with gastric IM were found to have an inverse association with pathology-proven duodenitis [OR 0.13 (0.02, 0.65), *P* = 0.012]. Furthermore, gastric IM was inversely associated with several esophageal histopathological diagnoses including Barrett’s esophagus [OR 0.28 (0.12, 0.63), *P* = 0.003], esophageal dysplasia [OR 0.11 (0.01, 0.64), *P* = 0.014], and eosinophilic esophagitis [OR 0.1 (0.0, 0.74), *P* = 0.02].

**DISCUSSION**

Although the incidence of gastric cancer is relatively low within the US, the 5-year survival for this disease remains poor. In large part, this is because gastric neoplasia is frequently diagnosed at an advanced stage when endoscopic and surgical therapies are less effective. There is a relative paucity of data concerning the frequency and significance of premalignant gastric lesions within the US population. Best estimates of the prevalence of gastric IM in patients undergoing EGD with biopsy is probably between 5%-7%[[27](#_ENREF_27),[31](#_ENREF_31)]. With an estimated 7 million EGDs done each year in the US[[33](#_ENREF_33)], this represents at least 350000 patients with gastric IM who could be diagnosed by the addition of a just a few gastric biopsies to these routine procedures.

Gastric IM is widely accepted as a premalignant lesion that can lead to gastric carcinoma[[10](#_ENREF_10)]. Uemura *et al*[[34](#_ENREF_34)] followed 1246 patients with *H. pylori* and gastric IM over a mean of 7.8 years and found that gastric cancer developed in 36 patients with a relative risk of 6.4 (2.6, 16.1), *P* < 0.001. In the present study, gastric IM was similarly associated with a six-fold increased odds ratio of finding gastric cancer [OR 6.53 (1.17, 139.41), *P* = 0.027].

*H. pylori* infection is recognized as one of the primary risk factors leading to the development of atrophic gastritis and gastric IM[[8](#_ENREF_8),[9](#_ENREF_9),[23](#_ENREF_23)], which is probably a consequence of having a long-term chronic inflammatory state. Our study demonstrated a statistically significant association between gastric IM and *H. pylori* infection [OR 3.07 (1.33, 8.19), *P* = 0.007], as might be expected. Several prior studies have attempted to induce regression of gastric IM through treatment of *H. pylori* infection with varying results. A recent metaanalysis by Wang *et al*[[35](#_ENREF_35)] included 12 studies and a total of 2658 patients with atrophic gastritis and gastric IM. They found that atrophic gastritis in the antrum can be reduced through treatment of *H. pylori* infection; however, atrophic gastritis in the corpus or gastric IM regardless of location in the stomach failed to regress with eradication of *H. pylori*. This observation that once gastric IM develops that subsequent *H. pylori* treatment might be ineffective supports the hypothesis that gastric IM is likely a breakpoint in the carcinogenic pathway leading to gastric cancer.

A large Dutch study by de Vries *et al*[[36](#_ENREF_36)] of 61707 patients with gastric IM found that 874 patients developed a new diagnosis gastric cancer when followed over 10 years. The annual incidence of gastric cancer among patients with gastric IM in this study was 0.25%. Although these patients were followed for a total of 10 years, the median interval between diagnosis of gastric IM and gastric cancer was only 0.9 years. These data take on new meaning when compared to the annual incidence of Barrett’s esophagus progressing to adenocarcinoma, which is estimated to range between 0.12% and 0.5%[[37](#_ENREF_37)]. Paradoxically, in the West, screening and surveillance guidelines for Barrett’s esophagus have been in place for over a decade, and they are widely practiced; whereas multi-society or multi-national consensus on the screening and surveillance for gastric IM is lacking in Western nations. In 2002, Whiting *et al*[[38](#_ENREF_38)] published a study conducted in the United Kingdom that examined if annual endoscopic surveillance could detect new cases of gastric cancer at an earlier and possibly curative stage. The study followed 1753 patients over 10 years, and 14 new cases of gastric cancer were diagnosed at earlier stages (67% were stage I and II *vs* 23% stage III or IV; *P* < 0.05).

Part of the difficulty in reaching North American guidelines is the lack of consensus among practicing gastroenterologists in the US regarding the management of gastric IM. Our group, in conjunction with University of Virginia Center for Survey Research, conducted a survey of American Society for Gastrointestinal Endoscopy (ASGE) members that resulted in 162 responding endoscopists (85% gastroenterologists, 82% men, from 32 states, 53% in private practice). This survey uncovered that while 56% of these physicians considered gastric IM to be a premalignant lesion, only 26% screen for gastric IM, but 42% survey for gastric IM (at a time interval anywhere between 6 mo and 5 years). Importantly, 97% of respondents felt that societal guidelines for management of premalignant gastric lesions would be beneficial to clinical practice[[39](#_ENREF_39)]. These results were further supported by a study by Vance *et al*[[40](#_ENREF_40)] that showed “variability in the knowledge and practice patterns of US endoscopists related to surveillance of gastric intestinal metaplasia”.

In the 2006 ASGE guideline, “The role of endoscopy in the surveillance of premalignant conditions of the upper GI tract,” it was stated that “endoscopic surveillance for gastric IM has not been extensively studied in the US and therefore cannot be uniformly recommended”. However, those guidelines did recommend that “patients at increased risk for gastric cancer due to ethnic background or family history may benefit from surveillance”[[22](#_ENREF_22)]. In this present study, family history of gastric cancer had an increased odd of being associated with the presence of gastric IM, but this finding was not significant, which could be due to a lack of power. European/ESGE guidelines published in 2012 recommended surveillance endoscopy for patients with extensive atrophic gastritis or gastric IM based on evidence from strong systematic reviews and large cohort studies. They did, however, note that future prospective studies were required to assess the cost-effectiveness of surveillance endoscopy in this patient population[[30](#_ENREF_30)]. In 2014, Areia *et al*[[41](#_ENREF_41)] conducted a cost-utility economic analysis from a societal perspective in Portugal using a Markov model and found that endoscopic surveillance every 3 years for patients with premalignant gastric conditions such as extensive atrophy or IM was cost-effective. Recently, Kim *et al*[[42](#_ENREF_42)] have advocated that “Gastric cancer screening with endoscopy should be considered in individuals who are immigrants from regions associated with a high risk of gastric cancer (East Asia, Russia, or South America) or who have a family history of gastric cancer. Those with findings of atrophic gastritis or intestinal metaplasia on screening endoscopy should undergo surveillance endoscopy every 1 to 2 years”.

Limitations of this present study include that it was a retrospective study conducted at a single academic medical center and that we did not have complete data on patient ethnicity to review. Data from 2010 from the US Census Bureau about Albemarle County, Virginia (which is where the University of Virginia is located) reports the following ethnic demographics for its residents: 63.7% are White, 16.3% are Hispanic or Latino, 12.6% are Black or African American, 4.8% are Asian, 0.9% are American Indian or Alaska Native, and 0.2% are Native Hawaiian or other Pacific Islander. As such, the vast majority of patients in our study were White, Hispanic, or Black. Despite including a large number of patients with gastric IM, which remains a somewhat uncommon finding in the US, our study could still be limited by a lack of statistical power.

In this study, we demonstrated that patients with biopsy-proven gastric IM were significantly more likely to be cigarette smokers and to have endoscopic findings of gastric atrophy, which should prompt at least gastric biopsies (preferably *via* systematic endoscopy for gastric mapping[[43](#_ENREF_43)] and with multiple biopsies taken from the antrum, incisura, lesser curve, and gastric body) during EGD to histopathologically confirm atrophic gastritis and also to screen for gastric IM. When multifocal, extensive, or incomplete gastric IM are found, we believe that surveillance endoscopy is reasonable, which we and others[[20](#_ENREF_20)] conduct at 3-year intervals in the absence of any dysplasia. If focal areas of dysplasia or early gastric cancers are found, then we offer endoscopic mucosal resection or endoscopic submucosal dissection[[44](#_ENREF_44),[45](#_ENREF_45)], when appropriate[[46](#_ENREF_46)], in addition to more frequent endoscopic surveillance. Again, in this context, our data demonstrated that the presence of gastric IM is clinically significant, as this condition was associated with the pathologic findings of gastric dysplasia and cancer.

Interestingly, our study showed that gastric IM appears to confer a protective effect against the development of esophageal pathology including esophagitis, Barrett’s esophagus, and esophageal dysplasia. The most likely etiology for this inverse relationship among gastric IM and these esophageal pathologies is the reduction in gastric acid secretion found in patients with atrophic gastritis and gastric IM.

In summary, we hope that the data presented in this study might be of use as guidelines and recommendations concerning the screening and surveillance of gastric IM and other premalignant gastric lesions in a US patient population are developed. Patients who smoke or have the endoscopic finding of atrophic gastritis are significantly more likely to also have gastric IM, and these risk factors should prompt screening gastric biopsies during EGD. Patients with gastric IM are at increased risk for developing gastric dysplasia and cancer, and a program of surveillance biopsies in these patients might be reasonable. Conversely, patients with gastric IM appear significantly less likely to be diagnosed with Barrett’s esophagus and esophageal dysplasia.

**COMMENTS**

***Background***

Gastric intestinal metaplasia (IM) is a precursor to gastric adenocarcinoma. However, there are no North American consensus recommendations as to which patients might benefit from esophagogastroduodenoscopy (EGD) with biopsy for screening or surveillance for gastric IM.

***Research frontiers***

Endoscopic technology has advanced significantly in the past two decades, and high-definition white-light endoscopy and advanced optical imaging techniques now allow accurate real-time diagnosis of luminal gastrointestinal disorders, which formerly required formal histopathologic review of biopsy specimens. Careful endoscopic examination remains critical to the correct diagnosis of conditions such as atrophic gastritis, gastric intestinal metaplasia, and early gastric cancers.

***Innovations and breakthroughs***

In Western nations and populations, the epidemiological risk of gastric IM has been largely ignored given the lower prevalence of gastric cancer, as compared to Asian, South American, and Eastern European populations. However, data are re-emerging that demonstrate that gastric IM can be an important problem in Western populations. In the present study, gastric IM was associated with a statistically significant six-fold increased odds ratio of finding gastric cancer. Being mindful of clinical demographic factors and findings on endoscopic evaluation of the stomach can assist in determining which patients might benefit from screening gastric biopsies. Proper diagnosis of gastric IM might also identify a patient population that might benefit from surveillance endoscopy.

***Applications***

Patients who smoke or have the endoscopic finding of atrophic gastritis are more likely to have gastric IM and should have screening gastric biopsies during EGD. Patients with gastric IM are at increased risk for having gastric dysplasia and cancer, and surveillance EGD with gastric biopsies in these patients might be reasonable.

***Terminology***

Gastric intestinal metaplasia is characterized by the replacement of the normal gastric glandular epithelium by a small-intestinal phenotype, and it is often accompanies or follows chronic *Helicobacter pylori* infection of the stomach. Dysplasia is an abnormal change to tissue (in this case the gastric epithelium) that is considered premalignant. EGD is a procedure performed using a flexible endoscope whereby endoscopic views of the upper gastrointestinal tract (esophagus, stomach and duodenum) are obtained. EGD can also enable sampling of the mucosa of the upper gastrointestinal tract, often by using cold biopsy forceps.

***Peer-review***

This is a valuable attempt to analyze IM with the development of gastric cancer. It is a well conducted and well written study.

 **REFERENCES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

2 **Ferlay J**, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 V1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 [Internet]. [accessed 2014 Mar 8]. Lyon, France: International Agency for Research on Cancer, 2013. Available from: URL: http://globocan.iarc.fr

3 **Frye JW**, Sauer BG, Gomez JM, Shami VM, Northup PG, Wang AY. Gastroenterologists lack consensus regarding if, how, and when to screen or survey for premalignant gastric lesions: Results of a pilot survey. *Am J Gastroenterol* 2012; **107**: S43-S44

4 **Hundahl SA**, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. *Cancer* 2000; **88**: 921-932 [PMID: 10679663]

5 **Yasuda K**, Shiraishi N, Suematsu T, Yamaguchi K, Adachi Y, Kitano S. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. *Cancer* 1999; **85**: 2119-2123 [PMID: 10326688 DOI: 10.1002/(SICI)1097-0142(19990515)85:10<2119::AID-CNCR4>3.0.CO;2-M]

6 **Nakamura K**, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. *Cancer* 1992; **70**: 1030-1037 [PMID: 1515980 DOI: 10.1002/1097-0142(19920901)70:5<1030::AID-CNCR2820700504>3.0.CO;2-C]

7 **Jaiswal M**, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G626-G634 [PMID: 11518674]

8 **De Luca A**, Iaquinto G. Helicobacter pylori and gastric diseases: a dangerous association. *Cancer Lett* 2004; **213**: 1-10 [PMID: 15312678 DOI: 10.1016/j.canlet.2004.06.006]

9 **Kim N**, Park RY, Cho SI, Lim SH, Lee KH, Lee W, Kang HM, Lee HS, Jung HC, Song IS. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. *J Clin Gastroenterol* 2008; **42**: 448-454 [PMID: 18344895 DOI: 10.1097/MCG.0b013e318046eac3]

10 **Correa P**. A human model of gastric carcinogenesis. *Cancer Res* 1988; **48**: 3554-3560 [PMID: 3288329]

11 **Cho SJ**, Choi IJ, Kim CG, Kook MC, Lee JY, Kim BC, Ryu KH, Nam SY, Kim YW. Risk factors associated with gastric cancer in patients with a duodenal ulcer. *Helicobacter* 2010; **15**: 516-523 [PMID: 21073608 DOI: 10.1111/j.1523-5378.2010.00805.x]

12 **de Vries AC**, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. *Helicobacter* 2007; **12** Suppl 2: 22-31 [PMID: 17991173 DOI: 10.1111/j.1523-5378.2007.00562.x]

13 **Rugge M**, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddell RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova international classification. *Am J Surg Pathol* 2000; **24**: 167-176 [PMID: 10680883]

14 **de Vries AC**, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; **134**: 945-952 [PMID: 18395075 DOI: 10.1053/j.gastro.2008.01.071]

15 **Leung WK**, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. *Aliment Pharmacol Ther* 2002; **16**: 1209-1216 [PMID: 12144569]

16 **Watanabe H**. Intestinal metaplasia -the effect of Acid on the gastric mucosa and gastric carcinogenesis-. *J Toxicol Pathol* 2010; **23**: 115-123 [PMID: 22272022 DOI: 10.1293/tox.23.115]

17 **Rugge M**, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. *Aliment Pharmacol Ther* 2010; **31**: 1104-1111 [PMID: 20180784 DOI: 10.1111/j.1365-2036.2010.04277.x]

18 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022]

19 **Tava F**, Luinetti O, Ghigna MR, Alvisi C, Perego M, Trespi E, Klersy C, Fratti C, Fiocca R, Solcia E. Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia. *Hum Pathol* 2006; **37**: 1489-1497 [PMID: 16949645 DOI: 10.1016/j.humpath.2006.05.012]

20 **Correa P**, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. *Am J Gastroenterol* 2010; **105**: 493-498 [PMID: 20203636 DOI: 10.1038/ajg.2009.728]

21 **Filipe MI**, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994; **57**: 324-329 [PMID: 8168991]

22 **Hirota WK**, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, Qureshi WA, Rajan E, Fanelli R, Wheeler-Harbaugh J, Baron TH, Faigel DO. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. *Gastrointest Endosc* 2006; **63**: 570-580 [PMID: 16564854 DOI: 10.1016/j.gie.2006.02.004]

23 **Yagi K**, Nakamura A, Sekine A. Intestinal metaplasia of gastric cardia and carditis in Japanese patients with Helicobacter pylori infection. *Digestion* 2004; **70**: 103-108 [PMID: 15375339 DOI: 10.1159/000080929]

24 **Correa P**. Chemoprevention of gastric cancer: has the time come? *J Clin Oncol* 2003; **21**: 270s-271s [PMID: 14645407 DOI: 10.1200/JCO.2003.09.135]

25 **Matsukura N**, Suzuki K, Kawachi T, Aoyagi M, Sugimura T, Kitaoka H, Numajiri H, Shirota A, Itabashi M, Hirota T. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. *J Natl Cancer Inst* 1980; **65**: 231-240 [PMID: 6931245]

26 **González CA**, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. *Int J Cancer* 2010; **127**: 2654-2660 [PMID: 20178099 DOI: 10.1002/ijc.25273]

27 **Sonnenberg A**, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. *Gastroenterology* 2010; **139**: 1894-1901.e2; quiz e12 [PMID: 20727889 DOI: 10.1053/j.gastro.2010.08.018]

28 **Wong BC**, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004; **291**: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]

29 **Rokkas T**, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. *Eur J Gastroenterol Hepatol* 2010; **22**: 1128-1133 [PMID: 20410824 DOI: 10.1097/MEG.0b013e3283398d37]

30 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

31 **Gomez JM**, Frye JW, Patrie JT, Sauer BG, Shami VS, Moskaluk CA, Wang AY. The presence of gastric intestinal metaplasia in patients undergoing EGD with biopsy is associated with a family history of gastric cancer in the United States. *J Gastroenterol Hepatol Res* 2013; **2**: 479-482

32 **Berry G**, Armitage P. Mid-P confidence intervals: A brief review. *The Statistician* 1995; **44**: 417-423 [DOI: 10.2307/2348891]

33 **Pohl H**, Robertson D, Welch HG. Repeated upper endoscopy in the Medicare population: a retrospective analysis. *Ann Intern Med* 2014; **160**: 154 [PMID: 24658692 DOI: 10.7326/M13-0046]

34 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

35 **Wang J**, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. *Digestion* 2011; **83**: 253-260 [PMID: 21282951 DOI: 10.1159/000280318]

36 **de Vries AC**, Haringsma J, de Vries RA, Ter Borg F, van Grieken NC, Meijer GA, van Dekken H, Kuipers EJ. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. *Helicobacter* 2010; **15**: 259-264 [PMID: 20633186 DOI: 10.1111/j.1523-5378.2010.00760.x]

37 **Gomez JM**, Wang AY. Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm. *Gastroenterol Hepatol* (N Y) 2014; **10**: 369-378 [PMID: 25013389]

38 **Whiting JL**, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. *Gut* 2002; **50**: 378-381 [PMID: 11839718 DOI: 10.1136/gut.50.3.378]

39 **Frye JW**, Gomez JM, Bleibel W, Shami VM, Sauer BG, Wang AY. Lack of consensus regarding management of gastric intestinal metaplasia among practicing gastroenterologists indicates a need for societal guidelines. *Gastrointest Endosc* 2013; **77**: AB261-262 [DOI: 10.1016/j.gie.2013.03.646]

40 **Vance RB**, Kubiliun N, Dunbar KB. How Do We Manage Gastric Intestinal Metaplasia? A Survey of Clinical Practice Trends for Gastrointestinal Endoscopists in the United States. *Dig Dis Sci* 2016; **61**: 1870-1878 [PMID: 26984230 DOI: 10.1007/s10620-016-4107-4]

41 **Areia M**, Dinis-Ribeiro M, Rocha Gonçalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. *Helicobacter* 2014; **19**: 425-436 [PMID: 25164596 DOI: 10.1111/hel.12150]

42 **Kim GH**, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? *Gastrointest Endosc* 2016; **84**: 18-28 [PMID: 26940296 DOI: 10.1016/j.gie.2016.02.028]

43 **Emura F**, Gralnek I, Baron TH. Improving early detection of gastric cancer: a novel systematic alphanumeric-coded endoscopic approach. *Rev Gastroenterol Peru* 2013; **33**: 52-58 [PMID: 23539057]

44 **Wang AY**, Emura F, Oda I, Cox DG, Kim HS, Yeaton P. Endoscopic submucosal dissection with electrosurgical knives in a patient on aspirin therapy (with video). *Gastrointest Endosc* 2010; **72**: 1066-1071 [PMID: 20869712 DOI: 10.1016/j.gie.2010.06.008]

45 **Wang AY**. The international emergence of endoscopic submucosal dissection for early gastric cancer. *Gastrointest Endosc* 2011; **73**: 928-931 [PMID: 21521565 DOI: 10.1016/j.gie.2011.01.016]

46 **Gotoda T**. Endoscopic resection of early gastric cancer. *Gastric Cancer* 2007; **10**: 1-11 [PMID: 17334711]

**P- Reviewer:** Qi F, Rakusic Z, Seow-Choen F **S- Editor:** Gong XM

 **L- Editor:** **E- Editor:**

**Table 1 Patient characteristics and their associations with gastric intestinal metaplasia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Gastric IM****(+)*****n* = 468** | **Gastric IM****(-)*****n* = 171** | **Univariate analysis** | **Multivariate analysis****[OR (95%CI)]** |
| Age (mean/ median, yr) | 61.0 /64.0 | 48.8 /53.0 | *P* < 0.001 | -- |
| Male sex | 208 (44.4%) | 77 (45.0%) | *P* = 0.928 | -- |
| Family history of gastric cancer | 23 (5.7%)1 | 5 (2.9%) | *P* = 0.557 | 1.38 (0.52, 4.25), *P* = 0.555 |
| Tobacco use | 214 (48.6%)2 | 61 (36.5%)3 | *P* = 0.007 | 1.73 (1.18, 2.55), *P* = 0.005 |
| Alcohol use | 100 (22.7%)2 | 46 (26.9%) | *P* = 0.219 | 0.76 (0.50, 1.16), *P* = 0.199 |
| H2-blocker use | 21 (5.1%)4 | 13 (7.6%) | *P* = 0.251 | 0.74 (0.35, 1.59), *P* = 0.426 |
| PPI use | 258 (62.6%)4 | 94 (55.6%) | *P* = 0.088 | 1.23 (0.84, 1.79), *P* = 0.282 |
| Medicare | 245 (52.4%) | 46 (26.9%) | *P* < 0.001 | 1.94 (1.20, 3.17), *P* = 0.007 |
| Medicaid | 24 (5.1%) | 27 (15.8%) | *P* = 0.003 | 0.57 (0.30, 1.09), *P* = 0.090 |
| Private insurance | 118 (25.2%) | 72 (42.1%) | *P* < 0.001 | 0.66 (0.44, 0.99), *P* = 0.047 |
| Uninsured | 68 (14.5%) | 32 (18.7%) | *P* = 0.885 | 1.04 (0.64, 1.71), *P* = 0.885 |

1Information about family history was missing from 65 patients who had gastric intestinal metaplasia; 2Information about social history was missing from 28 patients who had gastric intestinal metaplasia; 3Information about tobacco use was missing from 4 patients who did not have gastric intestinal metaplasia; 4Information about H2-blocker and/or PPI use was missing from 56 patients who had gastric intestinal metaplasia. IM: Intestinal metaplasia.

**Table 2** **Association among indications and gastric intestinal metaplasia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Frequency in patients with gastric IM1** | **Frequency in patients without gastric IM1** | **Univariate analysis** | **Multivariate analysis****[OR (95%CI)]** |
| Abdominal pain | 188 (41.7%) | 93 (54.4%) | *P* = 0.005 | 0.81 (0.55, 1.18), *P* = 0.267 |
| Weight loss | 63 (13.5%) | 21 (7.4%) | *P* = 0.014 | 1.81 (0.95, 3.66), *P* = 0.073 |
| GI bleed | 38 (8.4%) | 13 (7.6%) | *P* = 0.755 | 1.23 (0.63, 2.52), *P* = 0.558 |
| Nausea | 60 (13.3%) | 27 (15.8%) | *P* = 0.426 | 0.97 (0.58, 1.65), *P* = 0.903 |
| Dysphagia | 59 (13.1%) | 26 (15.2%) | *P* = 0.490 | 0.74 (0.44, 1.26), *P* = 0.259 |
| Barrett’s esophagus | 10 (2.2%) | 8 (4.7%) | *P* = 0.123 | 0.32 (0.12, 0.92), *P* = 0.034 |

1The denominator (n) used to calculate the percentage of patients by indication (in each row) may vary depending on what was available from the clinical records. IM: Intestinal metaplasia.

**Table 3** **Associations among endoscopic findings (prior to or without histopathology) and gastric intestinal metaplasia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Frequency in patients with gastric IM*****n* = 418** | **Frequency in patients without gastric IM*****n* = 171** | **Univariate analysis** | **Multivariate analysis****(OR, 95%CI)** |
| **Gastritis** | 100 (23.9%) | 37 (21.6%) | *P* = 0.557 | 1.34 (0.84, 2.08), *P* = 0.223 |
| **Atrophic gastritis** | 55 (13.2%) | 9 (5.3%) | *P* = 0.004 | 2.05 (1.00, 4.58), *P* = 0.051 |
| **Gastric mass** | 20 (4.8%) | 0 (0%) | *P* = 0.001 | 8.84 (1.88, ∞), *P* = 0.005 |
| **Gastric ulcer** | 42 (10.0%) | 11 (6.4%) | *P* = 0.163 | 1.42 (0.71, 3.01), *P* = 0.339 |
| **Gastric nodularity** | 71 (17.0%) | 33 (19.3%) | *P* = 0.503 | 0.74 (0.46, 1.20), *P* = 0.213 |
| **Linitis plastica** | 1 (0.2%) | 0 (0%) | *P* = 0.710 | 0.27 (0.01, ∞), *P* = 0.788 |
| **Esophagitis** | 28 (6.7%) | 23 (13.4%) | *P* = 0.011 | 0.49 (0.26, 0.91), *P* = 0.023 |
| **Esophageal mass** | 2 (0.5%) | 13 (7.6%) | *P* < 0.001 | 0.04 (0.01-0.16), *P* < 0.001 |
| **Barrett’s esophagus** | 21 (5.0%) | 13 (7.6%) | *P* = 0.235 | 0.56 (0.26, 1.21), *P* = 0.134 |
| **Duodenitis** | 17 (4.1%) | 11 (6.4%) | *P* = 0.234 | 0.69 (0.30, 1.60), *P* = 0.337 |
| **Duodenal polyp** | 8 (1.9%) | 0 (0%) | *P* = 0.063 | 4.21 (0.81, ∞), *P* = 0.081 |
| **Duodenal mass** | 4 (1.0%) | 0 (0%) | *P* = 0.253 | 1.58 (0.26, ∞), *P* = 0.353 |
| **Duodenal ulcer** | 2 (0.5%) | 2 (1.2%) | *P* = 0.407 | 0.21 (0.02, 2.20), *P* = 0.179 |

IM: Intestinal metaplasia.

**Table 4** **Association among histopathological biopsy results and gastric intestinal metaplasia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Frequency in patients with gastric IM*****n* = 468** | **Frequency in patients without gastric IM*****n* = 171** | **Univariate analysis** | **Multivariate analysis****(OR)** |
| Chronic gastritis | 265 (56.6%) | 55 (32.2%) | *P* < 0.001 | 2.56 (1.75, 3.76), *P* < 0.001 |
| Gastric polyp | 35 (7.5%) | 11 (6.4%) | *P* = 0.669 | 1.07 (0.53, 2.31), *P* = 0.861 |
| MALT lymphoma | 5 (1.1%) | 0 (0.0%) | *P* = 0.209 | 1.48 (0.26, ∞), *P* = 0.372 |
| Erosive gastritis | 1 (0.2%) | 6 (3.5%) | *P* = 0.002 | 0.06 (0.0, 0.43), *P* = 0.003 |
| *H. pylori* infection | 46 (9.8%) | 6 (3.5%) | *P* = 0.007 | 3.07 (1.33, 8.20), *P* = 0.007 |
| Gastric ulcer | 18 (3.8%) | 0 (0%) | *P* = 0.003 | 6.97 (1.47, ∞), *P* = 0.015 |
| Gastric dysplasia | 19 (4.1%) | 1 (0.6%) | *P* = 0.017 | 6.11 (1.07, 131.57), *P* = 0.038 |
| Gastric cancer | 21 (4.5%) | 1 (0.6%) | *P* = 0.010 | 6.53 (1.17, 139.41), *P* = 0.027 |
| Autoimmune metaplastic atrophic gastritis | 12 (2.6%) | 0 (0%) | *P* = 0.023 | 5.64 (1.36, ∞), *P* = 0.035 |
| Esophagitis | 5 (1.1%) | 5 (2.9%) | *P* = 0.125 | 0.36 (0.09, 1.41), *P* = 0.138 |
| Barrett’s esophagus | 14 (3.0%) | 13 (7.6%) | *P* = 0.016 | 0.28 (0.12, 0.63), *P* = 0.003 |
| Esophageal dysplasia | 2 (0.4%) | 4 (2.3%) | *P* = 0.053 | 0.11 (0.01, 0.64), *P* = 0.014 |
| Esophageal cancer | 1 (0.2%) | 1 (0.6%) | *P* = 0.535 | 0.13 (0.01, 9.88), *P* = 0.402 |
| Eosinophilic esophagitis | 1 (0.2%) | 6 (3.5%) | *P* = 0.002 | 0.10 (0.00, 0.74), *P* = 0.020 |
| Carcinoid tumor | 10 (2.1%) | 0 (0%) | *P* = 0.043 | 5.13 (1.02, ∞), *P* = 0.047 |
| Duodenitis | 2 (0.4%) | 6 (3.5%) | *P* = 0.006 | 0.13 (0.02, 0.65), *P* = 0.012 |
| Duodenal polyp | 5 (1.1%) | 1 (0.6%) | *P* = 0.645 | OR 1.2 (0.16, 29.49), *P* = 0.944 |
| Duodenal ulcer | 2 (0.4%) | 0 (0%) | *P* = 0.536 | OR 0.63 (0.07, ∞), *P* = 0.628 |

IM: Intestinal metaplasia; *H. pylori: Helicobacter pylori*.